Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2011-006131-38-GB
EUCTR2011-006131-38-GB
Active, not recruiting
Not Applicable

A multi-centre 3-year follow-up study to assess the durability of sustained virologic response in alisporivir treated chronic hepatitis C patients - NA

ovartis Pharma Services AG0 sites2,000 target enrollmentMay 10, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
ovartis Pharma Services AG
Enrollment
2000
Status
Active, not recruiting
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 10, 2012
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\-Written informed consent must be obtained before any assessment is performed
  • •\-Males or females must be aged 18 years or older
  • •\-Have previously completed a Novartis\-sponsored hepatitis C study and received alisporivir
  • •\-Have achieved SVR24
  • •\-Are able to comply with visit schedule
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 2000
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •\-Use of any investigational drugs within 5 half\-lives of enrollment, or within 30 days of that medication, whichever is longer
  • •\-Use or planned use to start a new course of hepatitis C therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesChronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.MedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2011-006132-24-GBovartis Pharma Services AG105
Active, not recruiting
Not Applicable
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studies
EUCTR2011-006132-24-HUovartis Pharma Services AG650
Active, not recruiting
Phase 3
A study to assess thedurability of sustained virologic response in Alisporivirtreatedchronic Hepatitis C patientsHealth Condition 1: null- chronic Hepatitis C
CTRI/2012/10/003066ovartis Healthcare Pvt Lt2,000
Active, not recruiting
Not Applicable
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesChronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.MedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2011-006132-24-ESovartis Farmaceutica, S.A.650
Active, not recruiting
Not Applicable
A 3-year follow-up study of chronic hepatitis C patients treated with alisporivir to assess durability of sustained virologic response
EUCTR2011-006131-38-ITOVARTIS FARMA2,000